TargetBeta
CD70
CD70 molecule · also CD27L, CD27-L, CD27LG, TNFSF7 · CD molecules
2 programs in company-led studies act on CD70, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Anti-CD70 CAR-expressing T Lymphocytesrule | Chongqing Precision Biotech | phase 1 | 66 running | – | NCIt |
| Anti-CD70/CD3 Bispecific Antibody INCA036873rule | Incyte | phase 1 | 11 running | CD3E | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Carcinoma, Renal Cell, 1 program
- Hematologic Neoplasms, 1 program
- Lupus Erythematosus, Systemic, 1 program
- Neoplasm Metastasis, 1 program
- Ovarian Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 31, 2026Anti-CD70 CAR-expressing T Lymphocytes · Chongqing Precision Biotech · phase 1 · NCT06215950
- Aug 18, 2028Anti-CD70/CD3 Bispecific Antibody INCA036873 · Incyte · phase 1 · NCT07195916
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.